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Background
Parkinson's disease (PD) is one of the most widespread
neurodegenerative diseases. A reduction of complex I
activity has been demonstrated in mitochondria of PD
patients. Recently, it was shown that chronic subcutane-
ous exposure to low doses of rotenone (an inhibitor of
mitochondrial NADH dehydrogenase and a commonly
used pesticide) caused highly selective nigrostriatal
dopaminergic lesions. However, while the behavioural
effects of rotenone administration are well characterised,
the mechanisms underlying rotenone action are unclear.
Recent studies are regarding nitric oxide (NO) as universal
neuronal messenger in the pathophysiology of neurode-
generative diseases. The aim of this work is to study mech-
anisms underlying oxidative damage of the various brain
areas of rats produced by rotenone and to investigate a
possible role of NO and lipid peroxidation (LPO) proc-
esses during chronic rotenone administration.
Materials and methods
Rotenone at a dose of 1.5 mg/kg i. p. or vehicle (natural
oil, 1 ml/kg) was administered to male Sprague-Dawley
rats daily for 10, 20, 30 and 60 days and NO and LPO
were measured in the frontal and prefrontal cortices, stria-
tum and nucleus accumbens (NAc). NO generation was
directly measured using electron paramagnetic resonance
spectroscopy. Specific indexes of LPO (i.e., thiobarbituric
acid reactive substances, TBARS) were measured spectro-
photometrically. Catalepsy was tested by measuring the
descent latency after 30 and 60 days using a bar and grid
test.
Results
NO levels in all studied brain structures of rats after the
first rotenone injection were not different from those of
the control group. In striatum and frontal cortex the level
of NO was increased on day 30 and day 60. In our study
on day 1 and 20 there were slight increases of TBARS in
the striatum and frontal cortex, but on day 30 and 60 the
amount of TBARS was two times greater as compared to
control in these regions. Rotenone-treated animals
showed a prolonged descent latency as compared to con-
trol animals after 60 injections of rotenone only. An
increase of descent latency from day 30 to 60 was not
observed.
Conclusion
The findings indicate that chronic administration of
rotenone at the low dose 1.5 mg/kg significantly enhances
the NO generation in all studied brain areas, especially in
the NAc and striatum. Moreover, the results provide the
first direct evidence that rotenone increases NO tissue lev-
els. The results of this study should advance the under-
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